中期因子与胃癌的相关性研究现状  

The Research Status Quo of the Dependablity between Midkine and Gastric Cancer

作　　者：赵志强[1] 卢辉山[1] 

机构地区：[1]福建医科大学附属协和医院肿瘤科,福州350001

出　　处：《医学综述》2008年第18期2766-2768,共3页Medical Recapitulate

摘　　要：中期因子(MK)作为肝素结合生长因子家族的一员,通过促有丝分裂和细胞增殖、促血管生成、诱导细胞恶性转化、抗凋亡等功能影响胃癌细胞的增殖、分化及凋亡。MK在胃癌中呈过表达,且血清MK水平与预后不良相关,因此,MK有望成为一种新的肿瘤标志物;随着RNA干涉及特异性启动子参与基因治疗技术的发展,MK可能成为肿瘤基因治疗的新靶点,本文就MK与胃癌的关系进行综述。Midkine（MK） , a heparin-binding growth factor, can regulate cell growth, survival and differentiation. MK is over-expressed in gastric cancer. And the serum midkine concentration is associated with prognosis. It may serve as a useful marker in the clinical follow-up of tumor. With the development of siRNA, MK may be developed as an effective anti-tumor agent. The relation between MK and gastric cancer is reviewed.

关 键 词：中期因子 肝素结合生长因子 肿瘤标志物 基因治疗 

分 类 号：R730.21[医药卫生—肿瘤]